Two double-blind placebo-controlled pilot studies of eicosapentaenoic acid in the treatment of schizophrenia

Abedin, 1999, The effects of dietary alpha-linolic acid compared with docosahexaenoic acid on brain, retina, liver and heart in the guinea pig, Lipids, 34, 475, 10.1007/s11745-999-0387-3 Albers, 1993, Phosopholipase A2 activity in serum of neuroleptic-naı̈ve psychiatric in patients, Pharmacopsychiatry, 26, 94, 10.1055/s-2007-1014349 1994 Bates, 1993, Docosahexaenoic acid (22:6, n-3) but not eicosapentaenoic acid (20:5, n-3) can induce neutrophil-mediated injury of cultured endothelial cells: involvement of neutrophil elastase, J. Leukoc. Biol., 54, 590, 10.1002/jlb.54.6.590 Christensen, 1998, Fat consumption and schizophrenia, Acta Psychiatr. Scand., 78, 587, 10.1111/j.1600-0447.1988.tb06388.x 1998, Adverse effects of the atypical antipsychotics, J. Clin. Psychiatry, 59, 17 Connor, 1997, Are fish oils beneficial in the prevention and treatment of coronary artery disease?, Am. J. Clin. Nutr., 66, 1020S, 10.1093/ajcn/66.4.1020S De Caterina, 1994, The omega-3 fatty acid docosahexaenoate reduces cytokine-induced expression of proatherogenic and proinflammatory proteins in human endothelial cells, Arterioscler. Thromb., 14, 1829, 10.1161/01.ATV.14.11.1829 Delion, 1996, Alpha-linolenic acid dietary deficiency alters age-related changes of dopaminergic and serotoninergic neurotransmission in the rat frontal cortex, J. Neurochem., 66, 1582, 10.1046/j.1471-4159.1996.66041582.x Eaton, 1992, Schizophrenia and rheumatoid arthritis: a review, Schizophr. Res., 6, 181, 10.1016/0920-9964(92)90001-L Finnen, 1991, Purification and characterisation of phospholipase A2 from human epidermis, Biochem. Soc. Trans., 19, 91, 10.1042/bst019091s Fukuzako, 1999, Changes in levels of phosphorus metabolites in temporal lobes of drug-naı̈ve schizophrenic patients, Am. J. Psychiatry, 156, 1205, 10.1176/ajp.156.8.1205 Gattaz, 1987, Increased plasma phospholipase-A2 activity in schizophrenic patients: reduction after neuroleptic therapy, Biol. Psychiatry, 22, 421, 10.1016/0006-3223(87)90164-8 Gattaz, 1990, Increased serum phospholipase-A2 activity in schizophrenia: a replication study, Biol. Psychiatry, 28, 495 Gattaz, 1995, Increased platelet phospholipase A2 activity in schizophrenia, Schizophr. Res., 16, 1, 10.1016/0920-9964(94)00060-L Gilbert, 1999, Opposite regulation of prostaglandin H synthase isoforms by eicosapentaenoic and docosahexaenoic acids, Lipids, 34, 219, 10.1007/BF02562296 Glen, 1994, A red cell membrane abnormality in a subgroup of schizophrenic patients: evidence for two diseases, Schizophr. Res., 12, 53, 10.1016/0920-9964(94)90084-1 Hitzemann, 1985, Characteristics of phospholipid methylation in human erythrocyte ghosts: relationship to the psychoses and affective disorders, Biol. Psychiatry, 20, 297, 10.1016/0006-3223(85)90042-3 Horrobin, 1991, Fatty acid levels in the brains of schizophrenics and normal controls, Biol. Psychiatry, 30, 795, 10.1016/0006-3223(91)90235-E Horrobin, 1998, The membrane phospholipid hypothesis as a biochemical basis for the neurodevelopmental hypothesis of schizophrenia, Schizophr. Res., 30, 193, 10.1016/S0920-9964(97)00151-5 Howe, 1999, Equal antithrombotic and triglyceride-lowering effectiveness of eicosapentaenoic acid-rich and docosahexaenoic acid-rich fish oil supplements, Lipids, 34, S307, 10.1007/BF02562326 Kane, 1992 Kay, 1987, The positive and negative syndrome scale (PANSS) for schizophrenia, Schizophr. Bull., 13, 261, 10.1093/schbul/13.2.261 Keshaven, 1993, Erythrocyte membrane phospholipids in psychotic patients, Psychiatry Res., 49, 89, 10.1016/0165-1781(93)90032-C Litman, 1996, A role for phospholipid polyunsaturation in modulating membrane protein function, Lipids, 31, S193, 10.1007/BF02637075 Loh, 1980, Role of membrane lipids in receptor mechanisms, Ann. Rev. Pharmacol. Toxicol., 20, 201, 10.1146/annurev.pa.20.040180.001221 Mahadik, 1994, Plasma membrane phospholipid and cholesterol distribution of skin fibroblasts from drug-naı̈ve patients at the onset of psychosis, Schizophr. Res., 13, 239, 10.1016/0920-9964(94)90048-5 Manku, 1983, Fatty acids in plasma and red cell membranes, Lipids, 18, 906, 10.1007/BF02534572 Marteinsdottir, 1998, Changes in dietary fatty acids alter phospholipid fatty acid composition in selected regions of rat brain, Prog. Neuropsychopharmacol. Biol. Psychiatry, 22, 1007, 10.1016/S0278-5846(98)00052-9 Mellor, 1996, Omega-3 fatty acid supplementation in schizophrenic patients, Human Psychopharmacol., 11, 39, 10.1002/(SICI)1099-1077(199601)11:1<39::AID-HUP742>3.0.CO;2-# Morrow, 1992, Identification of skin as a major site of prostaglandin D2 release following oral administration of niacin in humans, J. Invest. Dermatol., 98, 812, 10.1111/1523-1747.ep12499963 Noponen, 1993, Elevated PLA2 activity in schizophrenics and other psychiatric disorders, Biol. Psychiatry, 34, 641, 10.1016/0006-3223(93)90157-9 Obata, 1999, Eicosapentaenoic acid inhibits prostaglandin D2 generation by inhibiting cyclo-oxygenase-2 in cultured human mast cells, Clin. Exp. Allergy, 29, 1129, 10.1046/j.1365-2222.1999.00604.x Okuda, 1994, Eicosapentaenoic acid enhances intracellular free calcium in cultured human endothelial cells, Biochem. Med. Metab. Biol., 51, 166, 10.1006/bmmb.1994.1021 Pangerl, 1991, Increased platelet membrane lysophosphatidylcholine in schizophrenia, Biol. Psychiatry, 30, 837, 10.1016/0006-3223(91)90239-I Peet, 1995, Depleted red cell membrane essential fatty acids in drug-treated schizophrenic patients, J. Psychiatr. Res., 29, 227, 10.1016/0022-3956(95)00001-L Peet, 1997, Double-blind trial of fatty acid supplementation in the treatment of schizophrenia 1999 Pettegrew, 1991, Alterations in brain high-energy phosphate and membrane phospholipid metabolism in first-episode, drug-naı̈ve schizophrenics. A pilot study of the dorsal prefrontal cortex by in vivo phosphorus 31 nuclear magnetic resonance spectroscopy, Arch. Gen. Psychiatry, 48, 563, 10.1001/archpsyc.1991.01810300075011 Puri, 1998, Sustained remission of positive and negative symptoms of schizophrenia following treatment with eicosapentaenoic acid, Arch. Gen. Psychiatry, 55, 188, 10.1001/archpsyc.55.2.188 Ross, 1997, Increased phospholipid breakdown in schizophrenia: evidence for the involvement of a calcium-independent phospholipase A2, Arch. Gen. Psychiatry, 54, 487, 10.1001/archpsyc.1997.01830170113015 Ross, 1999, Brain and blood phospholipase activity in psychiatric disorders, 23 Rudin, 1981, The major psychoses and neuroses as omega-3 essential fatty acid deficiency syndrome: substrate pellagra, Biol. Psychiatry, 16, 837 Shah, 1998, Eicosapentaenoic acid (EPA) as an adjunct in the treatment of schizophrenia Shah, 2000, Lack of niacin skin flush response in unmedicated schizophrenic patients, Schizophr. Res Stanley, 1994, Membrane phospholipid metabolism and schizophrenia: in vivo 31P-MR spectroscopy study, Schizophr. Res., 13, 209, 10.1016/0920-9964(94)90044-2 Sumida, 1993, Role of fatty acids in signal transduction: modulators and messengers, Prostaglandins Leukot. Essent. Fatty Acids, 48, 117, 10.1016/0952-3278(93)90019-S Tisdale, 1993, Mechanism of lipid mobilisation associated with cancer cachexia: interaction between the polyunsaturated fatty acid, eicosapentaenoic acid and inhibitory guanine nucleotide-regulatory protein, Prostaglandins Leukot. Essent. Fatty Acids, 48, 105, 10.1016/0952-3278(93)90017-Q Trzeciak, 1995, Effect of neuroleptics on phospholipase A2 activity in the brain of rats, Eur. Arch. Psychiatry. Clin. Neurosci., 245, 179, 10.1007/BF02193092 Tsuang, 1999, Treatment of non-psychotic relatives of patients with schizophrenia: four case studies, Biol. Psychiatry, 45, 1412, 10.1016/S0006-3223(98)00364-3 Vaddadi, 1986, A controlled trial of a prostaglandin E1 precursor in chronic neuroleptic-resistant schizophrenic patients, Psychopharmacology, 88, 362, 10.1007/BF00180839 Vaddadi, 1989, A double blind trial of essential fatty acid supplementation in patients with tardive dyskinesia, Psychiatry Res., 27, 313, 10.1016/0165-1781(89)90146-7 Waddington, 1997, The new antipsychotics and their potential for early intervention in schizophrenia, Schizophr. Res., 28, 207, 10.1016/S0920-9964(97)00115-1 Ward, 1998, Niacin skin flush in schizophrenia a preliminary report, Schizophr. Res., 29, 269, 10.1016/S0920-9964(97)00100-X Warner, 1999, Retinal function as a marker for cell membrane omega-3 fatty acid depletion in schizophrenia: a pilot study, Biol. Psychiatry, 45, 1138, 10.1016/S0006-3223(98)00379-5 Willumsen, 1996, Eicosapentaenoic acid, but not docosahexaenoic acid, increases mitochondrial fatty acid oxidation and upregulates 2,4-dienoyl-CoA reductase gene expression in rats, Lipids, 31, 579, 10.1007/BF02523828 Wolkin, 1986, Essential fatty acid supplementation in tardive dyskinesia, Am. J. Psychiatry, 143, 912, 10.1176/ajp.143.7.912 Yao, 1994, Red blood cell membrane dynamics in schizophrenia II: fatty acid composition, Schizophr. Res., 13, 217, 10.1016/0920-9964(94)90045-0 Yao, 1994, Red blood cell membrane dynamics in schizophrenia III. Correlation of fatty acid abnormalities with clinical measures, Schizophr. Res., 13, 227, 10.1016/0920-9964(94)90046-9 Yao, 1999, Red blood cell and platelet fatty acid metabolism in schizophrenia, 57 Yokota, 1998, Modification of membrane phospholipids with n-6 and n-3 essential fatty acids regulates the gene expression of prostaglandin endoperoxide synthase isoforms upon agonist stimulation, 68 Yung, 1997, Is pre-psychotic intervention realistic in schizophrenia and related disorders?, Aust. NZ J. Psychiatry, 31, 799, 10.3109/00048679709065502 Yung, 1998, Prediction of psychosis. A step towards indicated prevention of schizophrenia, Br. J. Psychiatry, 172, 14, 10.1192/S0007125000297602